secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2026-05-22T21:15:41+00:00
Accession:  0001140361-26-022633
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris Technologies enters $250M ATM equity offering with TD Cowen to fund DurAVR heart valve development
--------------------------------------------------------------------------------

- Entered into Sales Agreement with TD Securities (USA) LLC for at-the-market offering of up to $250M of common stock.
- Commission payable to TD Cowen is 3.0% of gross proceeds for sales as agent.
- Net proceeds primarily for ongoing development of DurAVR Transcatheter Heart Valve System and working capital.
- Sales may be made on Nasdaq, in negotiated transactions, or block trades; company controls timing and size.
- Offering terminates upon sale of all shares or either party giving 10 days' notice; shelf effective since Jan 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126022633/0001140361-26-022633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126022633/ny20074564x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-022633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer